OA
TEVA icon

Operose Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Operose Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69K Hold
2,036
– – 0.01% 274
2026
Q1 		$61.3K Hold
2,036
– – 0.01% 259
2025
Q4 		$63.5K Hold
2,036
– – 0.01% 259
2025
Q3 		$41.1K Hold
2,036
– – 0.01% 276
2025
Q2 		$34.1K Hold
2,036
– – 0.01% 260
2025
Q1 		$31.3K Hold
2,036
– – 0.01% 246
2024
Q4 		$44.9K Hold
2,036
– – 0.02% 218
2024
Q3 		$36.7K Hold
2,036
– – 0.01% 314
2024
Q2 		$33.1K Hold
2,036
– – 0.01% 285
2024
Q1 		$28.7K Hold
2,036
– – 0.01% 326
2023
Q4 		$21.3K Hold
2,036
– – 0.01% 356
2023
Q3 		$20.8K Hold
2,036
– – 0.01% 475
2023
Q2 		$15.3K Hold
2,036
– – 0.01% 254
2023
Q1 		$18K Hold
2,036
– – 0.01% 235
2022
Q4 		$18.6K Buy
2,036
+36
+2% +$314 0.01% 225
2022
Q3 		$16K Buy
+2,000
New +$17.7K 0.01% 235

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Operose Advisors's TEVA Position: Q2 2026 in Review

Operose Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 2,036 shares worth $69K. The position accounts for 0.01% of the portfolio, ranked #274.

Operose Advisors first reported a position in TEVA in Q3 2022 and has held it in 16 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Operose Advisors held 2,036 shares of Teva Pharmaceuticals worth $69K as of Q2 2026.
  • Operose Advisors left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up 0.01% of Operose Advisors's portfolio in Q2 2026, its #274 holding.
  • Operose Advisors first reported a position in Teva Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.